Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

摘要

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

主权项

1. A kit comprising:
a. at least one nucleic acid probe designed to detect a nucleotide variance within exons 18, 19, 20 or 21 of the EGFR gene, wherein detection is based on specific hybridization to the nucleotide variance sequence, wherein the nucleotide variance comprises:
i) a substitution in exon 18 that results in an amino acid change consisting of a substitution of cysteine for glycine at position 719 (G719C) of SEQ ID NO:512, a substitution of serine for glycine at position 719 (G719S) of SEQ ID NO:512, or a substitution of alanine for glycine at position 719 (G719A) of SEQ ID NO:512;ii) an in-frame deletion in exon 19 that results in one or more amino acid changes comprising a deletion of at least amino acids leucine, arginine, and glutamic acid at position 747, 748, and 749 of SEQ ID NO:512;iii) a substitution in exon 20 that results in an amino acid change at position 790 of SEQ ID NO:512; oriv) a substitution in exon 21 that results in an amino acid change consisting of a substitution of arginine for leucine at position 858 (L858R) of SEQ ID NO:512, or a substitution of glutamine for leucine at position 861 (L861 Q) of SEQ ID NO:512; and wherein the nucleic acid probe comprises a detectable label; b. products and reagents required to carry out an annealing reaction; and c. instructions.